Doctor of Philosophy, Case Western Reserve University, 2024, Biomedical Engineering
Much of the human genome contains genes that do not encode proteins, but that are still transcribed into RNA that has essential functions toward regulating gene expression. Among these are long noncoding RNAs (lncRNA), a heterogeneous group of RNAs over 200 nucleotides in length that are often expressed in tissue-, disease-, or developmental stage-specific manners. In addition to its normal roles, lncRNA has been found to be deregulated in multiple human cancers, particularly aggressive ones like non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). NSCLC and TNBC are among the leading causes of cancer-related death globally, in part due to a lack of curative treatment options in a disease known to develop resistance to chemotherapies. Regulating the expression of oncogenic lncRNAs through RNA interference (RNAi) with small interfering RNA (siRNA) could serve as a promising strategy to inhibit tumor growth in aggressive cancers. To achieve the maximum benefit from siRNA therapy, it requires a proper delivery system to reach the site of interest. At the same time, non-invasively monitoring the effects of the therapy can assist in treatment planning and determining its success.
This dissertation focuses on delivering siRNA against a long noncoding RNA called DANCR, which is overexpressed in both NSCLC and TNBC, using a pH-sensitive amino lipid carrier, ECO, along with applying magnetic resonance molecular imaging (MRMI) to track the treatment progress. Silencing DANCR with ECO/siDANCR nanoparticles was previously shown to inhibit TNBC cell migration and invasion, but its effects in NSCLC had not been evaluated. Further, ECO/siDANCR nanoparticles were optimized to target a protein abundant in the tumor extracellular matrix but limited in normal tissue, extradomain B fibronectin (EDB-FN). A peptide specific to EDB-FN, ZD2, was previously developed and applied in this work for targeting ECO nanoparticles. At the same time, an EDB-targeted MRI co (open full item for complete abstract)
Committee: Zheng-Rong Lu (Advisor); William Schiemann (Committee Member); Horst von Recum (Committee Member); Samuel Senyo (Committee Chair)
Subjects: Biomedical Engineering